Things to Know When Talking About Race and Genetics
By Agustín Fuentes,
Psychology Today
| 05. 13. 2014
Untitled Document
On May 5th, 2014, I shared the platform in a webinar debate with Nicholas Wade (former NYTimes Science Writer) about his new book “A Troublesome Inheritance – A discussion on genes, race and human history.” The debate was sponsored by the American Anthropological Association.
Wade’s assertions in the book (and our discussion) are that Humans are divided into genetically identified “continental races” and that there are significant differences in genetically based social behaviors between these “races” as a result of the last 50,000 years of human evolution.
Wade argues that social scientists are covering up these ideas and claims that a true discussion on race is repressed by most academics out of political correctness. These points were also made by Charles Murray in a laudatory review of Wade’s book in the Wall Street Journal. They are both wrong.
I am an academic and I love to talk about the data on race, so do many of my colleagues. The scientific data on human genetic variation and human evolution refute the claims there are multiple biological races...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...